Nisa Investment Advisors LLC Buys 13,867 Shares of DexCom, Inc. (NASDAQ:DXCM)

Nisa Investment Advisors LLC lifted its stake in DexCom, Inc. (NASDAQ:DXCM) by 23.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 74,232 shares of the medical device company’s stock after acquiring an additional 13,867 shares during the period. Nisa Investment Advisors LLC’s holdings in DexCom were worth $5,773,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in DXCM. Versant Capital Management Inc bought a new position in DexCom in the fourth quarter worth about $25,000. Riverview Trust Co raised its stake in shares of DexCom by 100.4% during the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the third quarter valued at approximately $57,000. Covestor Ltd boosted its stake in DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock valued at $64,000 after acquiring an additional 335 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB grew its holdings in DexCom by 46.7% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock worth $65,000 after purchasing an additional 265 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

DXCM opened at $88.75 on Friday. The firm has a fifty day moving average price of $79.25 and a 200 day moving average price of $77.51. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The stock has a market cap of $34.67 billion, a P/E ratio of 53.14, a P/E/G ratio of 2.23 and a beta of 1.12. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12.

Analysts Set New Price Targets

DXCM has been the subject of a number of recent analyst reports. Citigroup raised their price objective on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group increased their price objective on shares of DexCom from $89.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Robert W. Baird raised shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Sanford C. Bernstein boosted their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a report on Friday, October 25th. Finally, Oppenheimer reduced their target price on DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $99.29.

Insiders Place Their Bets

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.